Dopamine D2/D3 receptors (pramipexole component) and Neurokinin-1 (NK1) receptor (aprepitant component)

Class

Fixed-dose combination product (ALTO-208): pramipexole (dopamine D2/D3 receptor agonist) plus aprepitant (NK1 receptor antagonist/antiemetic)

Pathway

Dopaminergic replacement via D2/D3 agonism combined with NK1 receptor antagonism, intended to improve tolerability/reduce dopamine-agonist-associated adverse effects

Dopamine D2/D3 receptors are proteins on brain cells, most densely found in circuits that control movement and reward. When dopamine-producing neurons are lost, as happens in Parkinson's disease, agonist drugs like pramipexole substitute for the missing dopamine by directly activating D2/D3 receptors, helping restore motor function. A common limitation of dopamine agonist therapy is nausea and vomiting, caused in part by stimulation of dopamine receptors in a brainstem region that lies outside the blood-brain barrier and constantly samples the bloodstream for substances that should trigger vomiting. Neurokinin-1 (NK1) receptors, activated by the signaling molecule substance P, sit in the same brainstem circuitry and are central to the vomiting reflex regardless of what originally provokes it. Pairing a D2/D3 agonist with an NK1 receptor antagonist such as aprepitant addresses this side effect directly: blocking NK1 signaling reduces nausea without interfering with the dopaminergic effect on movement. This reflects a general pharmacological strategy of combining a primary therapeutic agent with a mechanistically distinct one that offsets a known class-related adverse effect, potentially improving tolerability and adherence in movement disorders such as Parkinson's disease and restless legs syndrome.